Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 17/20 | 0.61 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442748 | 0.81 | GRM2 (0.63) | GRM2SLC9A1HCAR3 | |
| SCHEMBL16831208 | 0.81 | GRM2 (0.63) | GRM2SLC9A1HCAR3 | |
| SCHEMBL18325531 | 0.80 | GRM2 (0.61) | GRM2SLC9A1HCAR3 | |
| SCHEMBL31457669 | 0.78 | GRM2 (0.58) | GRM2SLC9A1HCAR3 | |
| SCHEMBL16832061 | 0.77 | LMNA (0.41) | GRM2SLC9A1HCAR3PTGER4 | |
| SCHEMBL31306003 | 0.77 | LMNA (0.41) | GRM2SLC9A1HCAR3PTGER4 | |
| SCHEMBL30665857 | 0.75 | GRM2 (0.55) | GRM2SLC9A1HCAR3 | |
| SCHEMBL25429341 | 0.73 | GRM2 (0.57) | GRM2SLC9A1HCAR3 | |
| SCHEMBL31339740 | 0.73 | GRM2 (0.57) | GRM2SLC9A1HCAR3 | |
| SCHEMBL20439751 | 0.70 | GRM2 (0.53) | GRM2SLC9A1HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782996-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| EP-3555078-B1 | BISARYL HETEROCYCLES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| EP-3555088-B1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-11-24 | — | — | EP | disclosed |
| EP-3555088-B1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-11-24 | — | — | EP | disclosed |
| US-11117905-B2 | Bisaryl heterocycles as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-09-14 | — | — | US | disclosed |
| US-11117905-B2 | Bisaryl heterocycles as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-09-14 | — | — | US | disclosed |
| US-11078216-B2 | Bisaryl amides as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-03 | — | — | US | disclosed |
| US-11078216-B2 | Bisaryl amides as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-03 | — | — | US | disclosed |
| EP-3555088-A1 | BISARYL AMIDES AS NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-23 | — | — | EP | disclosed |
| EP-3555078-A1 | BISARYL HETEROCYCLES AS NRF2 ACTI | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-23 | — | — | EP | disclosed |
| US-20180179187-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20180179187-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20180179187-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| WO-2018109643-A1 | BISARYL HETEROCYCLES AS NRF2 ACTI | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018109643-A1 | BISARYL HETEROCYCLES AS NRF2 ACTI | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018109647-A1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018109647-A1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| WO-2016202253-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078216-B2 | Bisaryl amides as NRF2 activators | NFE2L2, KEAP1, NQO1 | GRM2 2601/4885SLC9A1 3329/4885HCAR3 1162/4885 |
| US-20180179187-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | GRM2 2279/4885SLC9A1 4050/4885HCAR3 1805/4885 |
| US-20230047296-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | GRM2 1583/4885SLC9A1 3621/4885HCAR3 1386/4885 |
| US-11117905-B2 | Bisaryl heterocycles as NRF2 activators | NFE2L2, KEAP1, NQO1 | GRM2 2726/4885SLC9A1 3329/4885HCAR3 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.